Evidence map›Paper›PMID 35373118›Full record

ArticleKidney3602022

Short- and Long-Term Recovery after Moderate/Severe AKI in Patients with and without COVID-19.

Siao Sun, Raji R Annadi, Imran Chaudhri, Kiran Munir, Janos Hajagos, Joel Saltz, Minh Hoai, Sandeep K Mallipattu, Richard Moffitt, Farrukh M Koraishy

Open access · diamondAbstract read
In one paragraph

Article in Kidney360, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Kidney involvement and anemia in COVID-19 infection.World journal of nephrology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Siao SunDepartment of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New York.ORCID 0000-0001-7341-2231
Raji R AnnadiDepartment of Computer Science, Stony Brook University, Stony Brook, New York.
Imran ChaudhriDepartment of Medicine, Stony Brook University, Stony Brook, New York.
Kiran MunirDepartment of Medicine, Stony Brook University, Stony Brook, New York.
Janos HajagosDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, New York.
Joel SaltzDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, New York.ORCID 0000-0002-3451-2165
Minh HoaiDepartment of Computer Science, Stony Brook University, Stony Brook, New York.
Sandeep K MallipattuDivision of Nephrology and Hypertension, Department of Medicine, Stony Brook University, Stony Brook, New York.ORCID 0000-0002-6324-7807
Richard MoffittDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, New York.ORCID 0000-0003-2723-5902
Farrukh M KoraishyDivision of Nephrology and Hypertension, Department of Medicine, Stony Brook University, Stony Brook, New York.ORCID 0000-0001-6974-5674
Stony Brook University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe AKI is strongly associated with poor outcomes in coronavirus disease 2019 (COVID-19), but data on renal recovery are lacking. Methods: We retrospectively analyzed these associations in 3299 hospitalized patients (1338 with COVID-19 and 1961 with acute respiratory illness but who tested negative for COVID-19). Uni- and multivariable analyses were used to study mortality and recovery after Kidney Disease Improving Global Outcomes Stages 2 and 3 AKI (AKI-2/3), and Machine Learning was used to predict AKI and recovery using admission data. Long-term renal function and other outcomes were studied in a subgroup of AKI-2/3 survivors. Results: Among the 172 COVID-19-negative patients with AKI-2/3, 74% had partial and 44% complete renal recovery, whereas 12% died. Among 255 COVID-19 positive patients with AKI-2/3, lower recovery and higher mortality were noted (51% partial renal recovery, 25% complete renal recovery, 24% died). On multivariable analysis, intensive care unit admission and acute respiratory distress syndrome were associated with nonrecovery, and recovery was significantly associated with survival in COVID-19-positive patients. With Machine Learning, we were able to predict recovery from COVID-19-associated AKI-2/3 with an average precision of 0.62, and the strongest predictors of recovery were initial arterial partial pressure of oxygen and carbon dioxide, serum creatinine, potassium, lymphocyte count, and creatine phosphokinase. At 12-month follow-up, among 52 survivors with AKI-2/3, 26% COVID-19-positive and 24% COVID-19-negative patients had incident or progressive CKD. Conclusions: Recovery from COVID-19-associated moderate/severe AKI can be predicted using admission data and is associated with severity of respiratory disease and in-hospital death. The risk of CKD might be similar between COVID-19-positive and -negative patients.

Indexed as

Acute Kidney InjuryCOVID-19Hospital MortalityHumansRetrospective StudiesRisk FactorsSARS-CoV-2AKIAKI and ICU nephrologyCKDCOVID-19Machine Learningmortalityrecovery

Identifiers

PMID35373118
PMCPMC8967640
OpenAlexW3214771636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.